ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Abstract Number: 1429

Survival Outcomes in Elderly Patients with Axial Spondyloarthritis and Concomitant Cancer
Abstract Number: 1430

Redefining BASDAI cut-offs: implications for patients’ eligibility for initiating biologic disease-modifying antirheumatic treatment in axial spondyloarthritis
Abstract Number: 1431

Radiographic Sacroiliitis in Psoriatic Arthritis: Clinical, Laboratory, and Spinal Radiographic Correlates in an Indian Cohort
Abstract Number: 1432

Long-term Radiographic Progression in Early versus Established Axial Spondyloarthritis: A 12-Year Observational Study
Abstract Number: 1433

Identifying Predictors of Difficult-to-Manage Axial Spondyloarthritis: Real-World Insights from a Taiwanese Registry Cohort
Abstract Number: 1434

Safety of Prescription NSAIDs in Adults with IBD: Data from a Large Administrative Claims Cohort
Abstract Number: 1435

Impact of Treatment With Upadacitinib on Non-Nociceptive Pain and Its Relevance for the Presence of Residual Symptoms in Axial Spondyloarthritis: Results from a Multicountry Observational Study
Abstract Number: 1436

Angiogenesis Markers in Difficult to Treat Psoriatic Arthritis Patients
Abstract Number: 1437

Characterization of ORKA-002, a Novel Extended Half-life Monoclonal Antibody Targeting IL-17A/F for the Treatment of Psoriasis and Other Indications
Abstract Number: 1438

Similar Efficacy of Bimekizumab in Two Clinical Endotypes of Axial Spondyloarthritis: 2-Year Results from Two Phase 3 Studies and Their Open-Label Extension
Abstract Number: 1439

Bimekizumab in Psoriatic Arthritis. A real-world prospective study. Comparison of its efficacy in bDMARD-naive and IL-17A-experienced patients
Abstract Number: 1440

Comparison of standard and tapered dose of biologic treatments in patients with axial spondyloarthritis
Abstract Number: 1441

Efficacy and Safety of Vunakizumab in Patients with Active Ankylosing Spondylitis by Cigarette Smoking Status: A Post Hoc Analysis of a Randomized, Double-blind, Phase 2/3 Study
Abstract Number: 1442

Modulation of Soluble Biomarkers of Cartilage and Bone Turnover and Inflammation by Zasocitinib (TAK-279), an Oral, Allosteric, Highly Selective and Potent TYK2 Inhibitor, is Associated with Clinical Response in Patients with Active Psoriatic Arthritis
Abstract Number: 1443

Long-Term Safety and Efficacy of Upadacitinib in Patients With Psoriatic Arthritis: 5-Year Results From the Phase 3 SELECT-PsA 1 Study

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].